TerminatedPhase 1NCT02408861
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Studying Classic Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Lakshmi Rajdev, MDAIDS Malignancy Consortium
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 79 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2024
Study locations (30)
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- UC San Diego Medical Center - Hillcrest, San Diego, California, United States
- Zuckerberg San Francisco General Hospital, San Francisco, California, United States
- UCSF Medical Center-Mount Zion, San Francisco, California, United States
- UCSF Medical Center-Parnassus, San Francisco, California, United States
- George Washington University Medical Center, Washington D.C., District of Columbia, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- Siteman Cancer Center at Washington University, St Louis, Missouri, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02408861 on ClinicalTrials.govOther trials for Classic Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07275216Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentCity of Hope Medical Center
- RECRUITINGPHASE2NCT07209059PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaNational Research Center for Hematology, Russia
- RECRUITINGPHASE2NCT06984146Nivo40-AVD for Advanced Classic Hodgkin LymphomaNational Medical Research Radiological Centre of the Ministry of Health of Russia
- RECRUITINGPHASE2NCT06745076Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE1, PHASE2NCT06642792A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaAkeso
- RECRUITINGPHASE2NCT06377540MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE2NCT07234487Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHLSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE2NCT06812858PD-1 Inhibitors Maintenance for cHL Post-autoHCTSt. Petersburg State Pavlov Medical University